-
1
-
-
0030590746
-
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
-
CAPRIE Steering Committee
-
CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329-1339
-
(1996)
Lancet
, vol.348
, pp. 1329-1339
-
-
-
2
-
-
0037167686
-
Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups
-
Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators
-
Budaj A, Yusuf S, Mehta SR, et al; Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators. Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. Circulation. 2002;106:1622-1626
-
(2002)
Circulation
, vol.106
, pp. 1622-1626
-
-
Budaj, A.1
Yusuf, S.2
Mehta, S.R.3
-
3
-
-
20144373281
-
Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation
-
Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352:1179-1189
-
(2005)
N Engl J Med
, vol.352
, pp. 1179-1189
-
-
Sabatine, M.S.1
Cannon, C.P.2
Gibson, C.M.3
-
4
-
-
27644548513
-
-
Chen ZM, Jiang LX, Chen YP, et al COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: Randomised placebocontrolled trial. Lancet. 2005;366:1607-1621
-
(2005)
COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: Randomised placebocontrolled trial. Lancet
, vol.366
, pp. 1607-1621
-
-
Chen, Z.M.1
Jiang, L.X.2
Chen, Y.P.3
-
5
-
-
77958005516
-
Double-dose versus standard-dose clopidogrel and highdose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): A randomised factorial trial
-
CURRENT-OASIS 7 Trial Investigators
-
Mehta SR, Tanguay JF, Eikelboom JW, et al; CURRENT-OASIS 7 Trial Investigators. Double-dose versus standard-dose clopidogrel and highdose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): A randomised factorial trial. Lancet. 2010;376:1233-1243
-
(2010)
Lancet
, Issue.376
, pp. 1233-1243
-
-
Mehta, S.R.1
Tanguay, J.F.2
Eikelboom, J.W.3
-
6
-
-
34247869852
-
Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial
-
CHARISMA Investigators
-
Bhatt DL, Flather MD, Hacke W, et al CHARISMA Investigators. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007;49:1982-1988
-
(2007)
J Am Coll Cardiol
, vol.49
, pp. 1982-1988
-
-
Bhatt, D.L.1
Flather, M.D.2
Hacke, W.3
-
7
-
-
0037145863
-
Clopidogrel for the reduction of events during observation early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial
-
CREDO Investigators
-
Steinhubl SR, Berger PB, Mann JT III, et al CREDO Investigators. Clopidogrel for the reduction of events during observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA. 2002;288:2411-2420
-
(2002)
JAMA
, vol.288
, pp. 2411-2420
-
-
Steinhubl, S.R.1
Berger, P.B.2
Mann III, J.T.3
-
8
-
-
84455196353
-
Bioequivalence study of two clopidogrel film-coated tablet formulations in healthy volunteers
-
Setiawati E, Yunaidi DA, Handayani LR, et al. Bioequivalence study of two clopidogrel film-coated tablet formulations in healthy volunteers. Arzneimittelforschung. 2011;61:681-684
-
(2011)
Arzneimittelforschung
, Issue.61
, pp. 681-684
-
-
Setiawati, E.1
Yunaidi, D.A.2
Handayani, L.R.3
-
9
-
-
77958187538
-
Comparison of effects of two different formulations of clopidogrel bisulfate tablets on platelet aggregation and bleeding time in healthy Korean volunteers: A single-dose, randomized, open-label, 1-week, two-period, phase IV crossover study
-
Shim CY, Park S, Song JW, et al. Comparison of effects of two different formulations of clopidogrel bisulfate tablets on platelet aggregation and bleeding time in healthy Korean volunteers: A single-dose, randomized, open-label, 1-week, two-period, phase IV crossover study. Clin Ther. 2010;32:1664-1673
-
(2010)
Clin Ther
, Issue.32
, pp. 1664-1673
-
-
Shim, C.Y.1
Park, S.2
Song, J.W.3
-
10
-
-
77952299363
-
Bioequivalence of two tablet formulations of clopidogrel in healthy Argentinian volunteers: A single-dose, randomized-sequence, open-label crossover study
-
Di Girolamo G, Czerniuk P, Bertuola R, et al. Bioequivalence of two tablet formulations of clopidogrel in healthy Argentinian volunteers: A single-dose, randomized-sequence, open-label crossover study. Clin Ther. 2010;32:161-170
-
(2010)
Clin Ther
, Issue.32
, pp. 161-170
-
-
Di Girolamo, G.1
Czerniuk, P.2
Bertuola, R.3
-
11
-
-
77952507198
-
Clinical bioequivalence of a dose of clopidogrel Leti Cravid tablets 75 mg versus clopidogrel Sanofi Plavix tablets 75 mg administered on a daily dose for 7 days on healthy volunteers: A clinical trial
-
Müller A, Octavio J, González MY, et al. Clinical bioequivalence of a dose of clopidogrel Leti Cravid tablets 75 mg versus clopidogrel Sanofi Plavix tablets 75 mg administered on a daily dose for 7 days on healthy volunteers: A clinical trial. Am J Ther. 2010;17:351-356
-
(2010)
Am J Ther
, Issue.17
, pp. 351-356
-
-
Müller, A.1
Octavio, J.2
González, M.Y.3
-
12
-
-
71849117291
-
Bioequivalence of two oral formulations of clopidogrel tablets in healthy male volunteers
-
El Ahmady O, Ibrahim M, Hussein AM, et al. Bioequivalence of two oral formulations of clopidogrel tablets in healthy male volunteers. Int J Clin Pharmacol Ther. 2009;47:780-784
-
(2009)
Int J Clin Pharmacol Ther
, vol.47
, pp. 780-784
-
-
El Ahmady, O.1
Ibrahim, M.2
Hussein, A.M.3
-
13
-
-
65549122187
-
Single-dose randomized, open-label, 2-way crossover bioequivalence study of clopidogrel 75 mg tablet in healthy volunteers under fasting conditions
-
Filipe A, Almeida S, Franco Spínola AC, et al. Single-dose randomized, open-label, 2-way crossover bioequivalence study of clopidogrel 75 mg tablet in healthy volunteers under fasting conditions. Int J Clin Pharmacol Ther. 2009;47:187-194
-
(2009)
Int J Clin Pharmacol Ther
, vol.47
, pp. 187-194
-
-
Filipe, A.1
Almeida, S.2
Franco Spínola, A.C.3
-
14
-
-
77953691593
-
Clopidogrel and its salts: Any clinical implication?
-
Kummer O, Roffi M, Marti G, et al. Clopidogrel and its salts: Any clinical implication?. Rev Med Suisse. 2010;6:1127-1128
-
(2010)
Rev Med Suisse
, Issue.6
, pp. 1127-1128
-
-
Kummer, O.1
Roffi, M.2
Marti, G.3
-
15
-
-
25844468887
-
-
May 2009 plenary meeting monthly report Available at Accessed May 23
-
Committee for Medicinal Products for Human Use. May 2009 plenary meeting monthly report. Available at: Http://www.emea.europa.eu/docs/en-GB/ document-library/Committee-meeting-report/2009/10/WC500005831.pdf. Accessed May 23, 2012
-
(2012)
Committee For Medicinal Products For Human Use
-
-
-
16
-
-
84876416087
-
Generic clopidogrel besilate makes inroads into European Plavix market
-
Available at
-
Generic clopidogrel besilate makes inroads into European Plavix market. Available at: Http://cardiobrief.org/2010/01/21/generic-clopidogrel- besilatemakes- inroads-into-european-plavix-market/#more-4375. Accessed May 23, 2012
-
Accessed May
, vol.23
, pp. 2012
-
-
-
18
-
-
84876410953
-
In primary care, further to the Pharmaceutical Price Regulation Scheme (PPRS
-
Available at
-
in primary care, further to the Pharmaceutical Price Regulation Scheme (PPRS) 2009. Available at: Http://www.dh.gov.uk/en/Consultations/ Liveconsultations/DH-110517. Accessed May 23, 2012
-
(2009)
Accessed May
, vol.23
, pp. 2012
-
-
-
19
-
-
33749054883
-
Delaying generic competition - corporate payoffs and the future of Plavix
-
Shuchman M. Delaying generic competition - corporate payoffs and the future of Plavix. N Engl J Med. 2006;355:1297-1300
-
(2006)
N Engl J Med
, vol.355
, pp. 1297-1300
-
-
Shuchman, M.1
-
20
-
-
84876419974
-
-
Bristol-Myers Squibb And Sanofi-aventis Announce U.S. Available at Accessed May 23
-
Bristol-Myers Squibb and sanofi-aventis announce U.S. FDA decision to grant pediatric exclusivity for PLAVIX-. Available at: Http://www.sanofi- aventis. ph/l/ph/en/download.jsp?file=D5F3060C-C299-4074-89FE-E4393B6D431F. pdf. Accessed May 23, 2012
-
(2012)
FDA Decision To Grant Pediatric Exclusivity For PLAVIX
-
-
-
21
-
-
84876416558
-
-
IMS Health National Sales Perspectives Dec 2010 Available at Accessed May
-
IMS Health. The use of medicines in the United States: Review of 2010 National Sales Perspectives, Dec 2010. Available at: Http://www. imshealth.com/imshealth/Global/Content/IMS Institute/Documents/ IHII-UseOfMed-report.pdf. Accessed May 23, 2012
-
(2012)
Use of Medicines In The United States: Review Of 2010
, vol.23
-
-
-
23
-
-
70049099036
-
Assessing risk of bias in included studies Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated march 2011)
-
In: Higgins JPT, Green S, eds chap 8. Available at
-
Higgins JPT, Altman DG, Sterne JAC. Assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (Updated March 2011). The Cochrane Collaboration. 2011:chap 8. Available at: Www.cochrane-handbook.org
-
(2011)
Cochrane Collaboration
-
-
Higgins, J.P.T.1
Altman, D.G.2
Sterne, J.A.C.3
-
25
-
-
0037098201
-
Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes
-
Deeks JJ. Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. Stat Med. 2002;21:1575-1600
-
(2002)
Stat Med
, vol.21
, pp. 1575-1600
-
-
Deeks, J.J.1
-
26
-
-
84890783342
-
Analysing data and undertaking meta-analyses
-
In Higgins JPT, Green S, eds Updated March 2011). The Cochrane Collaboration chap 9
-
Deeks JJ, Higgins JPT, Altman DG, eds. Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (Updated March 2011). The Cochrane Collaboration; 2011:chap 9
-
(2011)
Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0
-
-
Deeks, J.J.1
Higgins, J.P.T.2
Altman, D.G.3
-
27
-
-
0001910889
-
Statistical methods for examining heterogeneity and combining results from several studies in metaanalysis
-
Egger M, Davey Smith G, Altman DG, eds 2nd ed. London, United Kingdom: BMJ Publication Group
-
Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in metaanalysis. In: Egger M, Davey Smith G, Altman DG, eds. Systematic Reviews in Health Care: Meta-Analysis in Context. 2nd ed. London, United Kingdom: BMJ Publication Group; 2001:313-335
-
(2001)
Systematic Reviews in Health Care: Meta-Analysis in Context
, pp. 313-335
-
-
Deeks, J.J.1
Altman, D.G.2
Bradburn, M.J.3
-
28
-
-
80051615049
-
Comparison of antiplatelet effect and tolerability of clopidogrel resinate with clopidogrel bisulfate in patients with coronary heart disease (CHD) or CHD-equivalent risks: A phase IV, prospective, double-dummy, parallel-group, 4-week noninferiority trial
-
Suh JW, Seung KB, Gwak CH, et al. Comparison of antiplatelet effect and tolerability of clopidogrel resinate with clopidogrel bisulfate in patients with coronary heart disease (CHD) or CHD-equivalent risks: A phase IV, prospective, double-dummy, parallel-group, 4-week noninferiority trial. Clin Ther. 2011;33:1057-1068
-
(2011)
Clin Ther
, Issue.33
, pp. 1057-1068
-
-
Suh, J.W.1
Seung, K.B.2
Gwak, C.H.3
-
29
-
-
79958037331
-
The impact of generic form of Clopidogrel on cardiovascular events in patients with coronary artery stent: Results of the OPCES study
-
Khosravi AR, Pourmoghadas M, Ostovan M, et al. The impact of generic form of Clopidogrel on cardiovascular events in patients with coronary artery stent: Results of the OPCES study. J Res Med Sci. 2011;16:640-650
-
(2011)
J Res Med Sci
, Issue.16
, pp. 640-650
-
-
Khosravi, A.R.1
Pourmoghadas, M.2
Ostovan, M.3
-
30
-
-
80054096419
-
Comparison of efficacy and safety of treatment with drugs of clopidogrel in patients after coronary artery stenting
-
Avdeeva LV, Shtegman OA, Mosina VA. Comparison of efficacy and safety of treatment with drugs of clopidogrel in patients after coronary artery stenting. Kardiologiia. 2011;51:23-26
-
(2011)
Kardiologiia
, Issue.51
, pp. 23-26
-
-
Avdeeva, L.V.1
Shtegman, O.A.2
Mosina, V.A.3
-
31
-
-
57549093120
-
Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: A systematic review and meta-analysis
-
Kesselheim AS, Misono AS, Lee JL, et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: A systematic review and meta-analysis. JAMA. 2008;300:2514-2526
-
(2008)
JAMA
, vol.300
, pp. 2514-2526
-
-
Kesselheim, A.S.1
Misono, A.S.2
Lee, J.L.3
-
32
-
-
80051826982
-
Quality of reporting of bioequivalence trials comparing generic to brand name drugs: A methodological systematic review
-
van der Meersch A, Dechartres A, Ravaud P. Quality of reporting of bioequivalence trials comparing generic to brand name drugs: A methodological systematic review. PLoS One. 2011;6:e23611
-
(2011)
PLoS One
, Issue.6
-
-
Van Der Meersch, A.1
Dechartres, A.2
Ravaud, P.3
-
33
-
-
84876416325
-
FDA guidance for industry - bioavailability and bioequivalence studies for orally administered drugs products - general considerations
-
Available at
-
FDA guidance for industry - bioavailability and bioequivalence studies for orally administered drugs products - general considerations. Available at: Http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory Information/Guidances/ucm070124.pdf. Accessed May 23, 2012
-
Accessed May
, vol.23
, pp. 2012
-
-
-
34
-
-
84876416087
-
EMEA Committee for Medicinal Products for Human Use (CMPH). Guideline on the investigation of bioequivalence
-
Available at
-
EMEA Committee for Medicinal Products for Human Use (CMPH). Guideline on the investigation of bioequivalence. Available at: Http://www.ema. europa.eu/pdfs/human/qwp/140198enrev1fin.pdf. Accessed May 23, 2012
-
Accessed May
, vol.23
, pp. 2012
-
-
-
35
-
-
77949936751
-
Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: A systematic review and meta-analysis
-
Kesselheim AS, Stedman MR, Bubrick EJ, et al. Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: A systematic review and meta-analysis. Drugs. 2010;70:605-621
-
(2010)
Drugs
, Issue.70
, pp. 605-621
-
-
Kesselheim, A.S.1
Stedman, M.R.2
Bubrick, E.J.3
-
36
-
-
0038439242
-
Pharmaceutical industry sponsorship and research outcome and quality: Systematic review
-
Lexchin J, Bero LA, Djulbegovic B, et al. Pharmaceutical industry sponsorship and research outcome and quality: Systematic review. BMJ. 2003; 326:1167-1170
-
(2003)
BMJ
, vol.326
, pp. 1167-1170
-
-
Lexchin, J.1
Bero, L.A.2
Djulbegovic, B.3
-
37
-
-
33750036086
-
Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: Systematic review
-
Jørgensen AW, Hilden J, Gøtzsche PC. Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: Systematic review. BMJ. 2006;333:782
-
(2006)
BMJ
, vol.333
, pp. 782
-
-
Jørgensen, A.W.1
Hilden, J.2
Gøtzsche, P.C.3
-
39
-
-
33845331688
-
Patients' attitudes towards and experiences of generic drug substitution in Norway
-
Kjoenniksen I, Lindbaek M, Granas A. Patients' attitudes towards and experiences of generic drug substitution in Norway. Pharm World Sci. 2006;28:284-289
-
(2006)
Pharm World Sci
, vol.28
, pp. 284-289
-
-
Kjoenniksen, I.1
Lindbaek, M.2
Granas, A.3
-
40
-
-
78751690811
-
Do people regard cheaper medicines effective? Population survey on public opinion of generic substitution in Finland
-
Heikkilä R, Mäntyselkä P, Ahonen R. Do people regard cheaper medicines effective? Population survey on public opinion of generic substitution in Finland. Pharmacoepidemiol Drug Saf. 2011;20:185-191
-
(2011)
Pharmacoepidemiol Drug Saf
, Issue.20
, pp. 185-191
-
-
Heikkilä, R.1
Mäntyselkä, P.2
Ahonen, R.3
-
41
-
-
83455162856
-
Price, familiarity, and availability determine the choice of drug - A population-based survey five years after generic substitution was introduced in Finland
-
Heikkilä R, Mäntyselkä P, Ahonen R. Price, familiarity, and availability determine the choice of drug - a population-based survey five years after generic substitution was introduced in Finland. BMC Clin Pharmacol. 2011;11:20
-
(2011)
BMC Clin Pharmacol
, Issue.11
, pp. 20
-
-
Heikkilä, R.1
Mäntyselkä, P.2
Ahonen, R.3
-
42
-
-
32644435800
-
The implications of choice: Prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions
-
Shrank WH, Hoang T, Ettner SL, et al. The implications of choice: Prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med. 2006;166:332-337
-
(2006)
Arch Intern Med
, vol.166
, pp. 332-337
-
-
Shrank, W.H.1
Hoang, T.2
Ettner, S.L.3
-
43
-
-
77953431835
-
Delays in filling clopidogrel prescription after hospital discharge and adverse outcomes after drug-eluting stent implantation: Implications for transitions of care
-
Ho PM, Tsai TT, Maddox TM, et al. Delays in filling clopidogrel prescription after hospital discharge and adverse outcomes after drug-eluting stent implantation: Implications for transitions of care. Circ Cardiovasc Qual Outcomes. 2010;3:261-266
-
(2010)
Circ Cardiovasc Qual Outcomes
, Issue.3
, pp. 261-266
-
-
Ho, P.M.1
Tsai, T.T.2
Maddox, T.M.3
-
44
-
-
77956695087
-
Evidence-based pharmacotherapy after myocardial infarction in France: Adherence-associated factors and relationship with 30-month mortality and rehospitalization
-
Tuppin P, Neumann A, Danchin N, et al. Evidence-based pharmacotherapy after myocardial infarction in France: Adherence-associated factors and relationship with 30-month mortality and rehospitalization. Arch Cardiovasc Dis. 2010;103:363-375
-
(2010)
Arch Cardiovasc Dis
, Issue.103
, pp. 363-375
-
-
Tuppin, P.1
Neumann, A.2
Danchin, N.3
-
45
-
-
54949142220
-
Cardiovascular outcomes after a change in prescription policy for clopidogrel
-
Jackevicius CA, Tu JV, Demers V, et al. Cardiovascular outcomes after a change in prescription policy for clopidogrel. N Engl J Med. 2008;359: 1802-1810
-
(2008)
N Engl J Med
, vol.359
, pp. 1802-1810
-
-
Jackevicius, C.A.1
Tu, J.V.2
Demers, V.3
-
46
-
-
32344435090
-
Generic substitution of antihypertensive drugs: Does it affect adherence?
-
Van Wijk BL, Klungel OH, Heerdink ER, et al. Generic substitution of antihypertensive drugs: Does it affect adherence? Ann Pharmacother. 2006;40:15-20
-
(2006)
Ann Pharmacother
, vol.40
, pp. 15-20
-
-
Van Wijk, B.L.1
Klungel, O.H.2
Heerdink, E.R.3
|